A carregar...
Safinamide in the management of patients with Parkinson’s disease not stabilized on levodopa: a review of the current clinical evidence
Safinamide (Xadago(®)) is a novel medication with both dopaminergic and non-dopaminergic effects, approved first by the European Commission and more recently by the US Food and Drug Administration (FDA) as an adjunctive treatment to carbidopa/levodopa in patients with mid- to late-stage Parkinson’s...
Na minha lista:
| Publicado no: | Ther Clin Risk Manag |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6152599/ https://ncbi.nlm.nih.gov/pubmed/30271159 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S139545 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|